{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:16:01Z","timestamp":1773278161816,"version":"3.50.1"},"reference-count":35,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fonds de Recherche du Qu\u00e9bec en Sant\u00e9"},{"DOI":"10.13039\/501100001804","name":"Canada Research Chair","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The value of serial bone mineral density (BMD) monitoring while on osteoporosis therapy is controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We determined the percentage of women classified as suboptimal responders to therapy with antiresorptive medications according to 2 definitions of serial BMD change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a cohort study using administrative databases at a single-payer government health system in Manitoba, Canada. Participants were postmenopausal women aged 40 years or older receiving antiresorptive medications and having 3 sequential BMD measures. Women stopping or switching therapies were excluded. The percentage of women whose spine or hip BMD decreased significantly during the first or second interval of monitoring by BMD was determined. Suboptimal responder status was defined as BMD decrease during both monitoring intervals or BMD decreased from baseline to final BMD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 1369 women in the analytic cohort. Mean BMD monitoring intervals were 3.0 (0.8) and 3.2 (0.8) years. In the first interval, 3.2% and 6.5% of women had a decrease in spine or hip BMD; 8.0% and 16.9% had decreases in the second monitoring interval; but only 1.4% showed repeated losses in both intervals. Considering the entire treatment interval, only 3.2% and 7.4% showed BMD loss at spine or hip. Results may not apply to situations of poor adherence to antiresorptive medication or anabolic therapy use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among women highly adherent to antiresorptive therapy for osteoporosis, a very small percentage sustained BMD losses on repeated measures. The value of multiple serial BMD monitoring to detect persistent suboptimal responders should be questioned.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab211","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T19:06:54Z","timestamp":1617131214000},"page":"2718-2725","source":"Crossref","is-referenced-by-count":10,"title":["Diminishing Value from Multiple Serial Bone Densitometry in Women Receiving Antiresorptive Medication for Osteoporosis"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-9360","authenticated-orcid":false,"given":"Gregory A","family":"Kline","sequence":"first","affiliation":[{"name":"Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne N","family":"Morin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M","family":"Lix","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Manitoba, Winnipeg, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D","family":"Leslie","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and Radiology, Rady College of Medicine, University of Manitoba, Winnipeg, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"5","key":"2021120108545691100_CIT0001","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00198-019-05183-4","article-title":"Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data","volume":"31","author":"Ding","year":"2020","journal-title":"Osteoporos Int."},{"issue":"4","key":"2021120108545691100_CIT0002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med."},{"issue":"4","key":"2021120108545691100_CIT0003","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021120108545691100_CIT0004","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.berh.2009.09.007","article-title":"Monitoring osteoporosis treatment","volume":"23","author":"Compston","year":"2009","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"1","key":"2021120108545691100_CIT0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00198-016-3720-6","article-title":"Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment\u2014a Danish case-control study","volume":"28","author":"Hansen","year":"2017","journal-title":"Osteoporos Int."},{"key":"2021120108545691100_CIT0006","first-page":"483","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up","author":"Sambrook","year":"2004"},{"issue":"1","key":"2021120108545691100_CIT0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","article-title":"Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint","volume":"23","author":"Marcus","year":"2002","journal-title":"Endocr Rev."},{"key":"2021120108545691100_CIT0008","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","author":"Bouxsein","year":"2019;34(4):632-642","journal-title":"J Bone Miner Res."},{"key":"2021120108545691100_CIT0009","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocr Metab"},{"issue":"1","key":"2021120108545691100_CIT0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int."},{"key":"2021120108545691100_CIT0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract."},{"issue":"7","key":"2021120108545691100_CIT0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/M15-2937","article-title":"Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: a registry-based cohort study","volume":"165","author":"Leslie","year":"2016","journal-title":"Ann Intern Med."},{"issue":"10","key":"2021120108545691100_CIT0013","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jbmr.3813","article-title":"Association of bone density monitoring in routine clinical practice with anti-osteoporosis medication use and incident fractures: a matched cohort study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2021120108545691100_CIT0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.2986","article-title":"Serial bone density measurement and incident fracture risk discrimination in postmenopausal women","author":"Crandall","year":"2020;180(9):1232-1240","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2021120108545691100_CIT0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1359\/jbmr.1997.12.1.124","article-title":"Sources of variability in bone mineral density measurements: implications for study design and analysis of bone loss","volume":"12","author":"Nguyen","year":"1997","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2021120108545691100_CIT0016","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00198-005-0050-5","article-title":"Patient variables impact lumbar spine dual energy X-ray absorptiometry precision","volume":"17","author":"Blank","year":"2006","journal-title":"Osteoporos Int."},{"issue":"1","key":"2021120108545691100_CIT0017","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1385\/JCD:7:1:93","article-title":"Seasonal variation in bone density in postmenopausal women","volume":"7","author":"Gerdhem","year":"2004","journal-title":"J Clin Densitom."},{"issue":"2","key":"2021120108545691100_CIT0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/JCD:3:2:107","article-title":"Interpretation of bone mineral density measurement and its change","volume":"3","author":"Nguyen","year":"2000","journal-title":"J Clin Densitom."},{"issue":"2","key":"2021120108545691100_CIT0019","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1210\/jc.2014-3777","article-title":"Why does rate of bone density loss not predict fracture risk?","volume":"100","author":"Leslie","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021120108545691100_CIT0020","first-page":"64","article-title":"Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?","volume":"4","author":"Li","year":"2004","journal-title":"J Musculoskelet Neuronal Interact."},{"issue":"3","key":"2021120108545691100_CIT0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1385\/JCD:6:3:275","article-title":"Establishing a regional bone density program: lessons from the Manitoba experience","volume":"6","author":"Leslie","year":"2003","journal-title":"J Clin Densitom."},{"issue":"11","key":"2021120108545691100_CIT0022","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1345\/aph.18117","article-title":"Validation of an electronic, population-based prescription database","volume":"32","author":"Kozyrskyj","year":"1998","journal-title":"Ann Pharmacother."},{"issue":"4","key":"2021120108545691100_CIT0023","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF01774016","article-title":"Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques","volume":"5","author":"Gl\u00fcer","year":"1995","journal-title":"Osteoporos Int."},{"issue":"11","key":"2021120108545691100_CIT0024","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1359\/jbmr.1999.14.11.1952","article-title":"Monitoring skeletal changes by radiological techniques","volume":"14","author":"Gl\u00fcer","year":"1999","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2021120108545691100_CIT0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jocd.2006.05.005","article-title":"Cross-calibration and minimum precision standards for dual-energy x-ray absorptiometry: the 2005 ISCD official positions","volume":"9","author":"Shepherd","year":"2006","journal-title":"J Clin Densitom."},{"issue":"2","key":"2021120108545691100_CIT0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1359\/jbmr.071019","article-title":"Factors affecting short-term bone density precision assessment and the effect on patient monitoring","volume":"23","author":"Leslie","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2021120108545691100_CIT0027","doi-asserted-by":"crossref","first-page":"b2266","DOI":"10.1136\/bmj.b2266","article-title":"Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data","volume":"338","author":"Bell","year":"2009","journal-title":"BMJ."},{"issue":"6","key":"2021120108545691100_CIT0028","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-149-6-200809160-00007","article-title":"Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American college of physicians","volume":"149","author":"Qaseem","year":"2008","journal-title":"Ann Intern Med."},{"issue":"10","key":"2021120108545691100_CIT0029","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1359\/jbmr.090818","article-title":"Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis","volume":"24","author":"Watts","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2021120108545691100_CIT0030","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int."},{"issue":"10","key":"2021120108545691100_CIT0031","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean","volume":"283","author":"Cummings","year":"2000","journal-title":"J Am Med Assoc."},{"issue":"10","key":"2021120108545691100_CIT0032","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1210\/jcem.85.10.6960","article-title":"Monitoring osteoporosis therapy with bone densitometry: a vital tool or regression toward mediocrity?","volume":"85","author":"Bonnick","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021120108545691100_CIT0033","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","article-title":"Risk of fracture among women who lose bone density during treatment with alendronate. the fracture intervention trial","volume":"16","author":"Chapurlat","year":"2005","journal-title":"Osteoporos Int."},{"issue":"1","key":"2021120108545691100_CIT0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021120108545691100_CIT0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jbmr.3194","article-title":"The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures","volume":"33","author":"Black","year":"2018","journal-title":"J Bone Miner Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab211\/36824197\/dgab211.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/2718\/41379056\/dgab211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/2718\/41379056\/dgab211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:47:21Z","timestamp":1638366441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/9\/2718\/6204740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,3,30]]},"published-print":{"date-parts":[[2021,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab211","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,3,30]]}}}